CHARLOTTE CHANCE: Open Payments
NPI 1326407396 · GRAND JUNCTION, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$176 in 9 payments from 7 companies in 2025. Trend: 2023 $453 · 2024 $379 · 2025 $176
Food & beverage: $176
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 3 | $54 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Seqirus USA Inc | 1 | $26 |
| Merck Sharp & Dohme LLC | 1 | $22 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| AstraZeneca Pharmaceuticals LP | 1 | $14 |
Products named: MOUNJARO, GEMTESA, Flucelvax, GARDASIL 9, JARDIANCE, XIFAXAN, VOQUEZNA, AIRSUPRA.
Industry payments across CO — which companies pay providers there.
